



H 74

SECTOR

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Reissue Application of: URANO et al.

Serial No.: 09/810, 650

ATTN: BOX MISSING PARTS

Filed: March 15, 2001

Group Art Unit: 1613

FOR: DIAZODISULFONES

RESPONSE TO NOTICE TO FILE MISSING PARTS

**Commissioner for Patents
Washington, D.C. 20231**

June 6, 2001

Dear Sir:

In response to the Notice to File Missing Parts of the Reissue Application dated April 16, 2001, enclosed for filing is an Executed Declaration and Power of Attorney for the above-identified patent application.



Also enclosed is our check in the amount of **\$130.00**, and the surcharge fee of **\$130.00** for filing the late Declaration. In the event that any additional fees are due with this paper, please charge Deposit Account No. 01-2340. This paper is filed in triplicate.

Respectfully submitted,

**ARMSTRONG, WESTERMAN, HATTORI
MCLELAND & NAUGHTON, LLP**

**Daniel A. Geselowitz, Ph.D.
Agent for Applicants
Reg. No. 42,573**

Atty. Docket No. 910094RI
Suite 1000
1725 K Street, N.W.
Washington, D.C. 20006
(202) 659-2930
DAG/srb





1613

3
RECEIVED

JUN 11 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Fumiyoshi URANO et al.

TECH CENTER 1600/2900

Serial No.: 09/810,650

Group Art Unit: 1613

Filed: March 15, 2001

Examiner: To be assigned

For: DIAZODISULFONES

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 CFR 1.97(b)

Commissioner for Patents
Washington, D.C. 20231

June 7, 2001

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-1449. One copy of each of these documents is attached.


No fee or certification is required in connection with this Information Disclosure Statement, since it is being submitted prior to the issuance of a first official action on the merits or expiration of the three month period following the filing date or the entry of the national stage of the above-captioned application.

The above information is presented so that the Patent and Trademark Office can, in the first instance, determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents cited in the attached Form PTO-1449 be made of record therein and appear on the first page of any patent to issue therefrom.

The Commissioner is authorized to charge our Deposit Account No. 01-2340 for any fee which is deemed by the Patent and Trademark Office to be required to effect consideration of this statement.

Respectfully submitted,

ARMSTRONG, WESTERMAN, HATTORI,
McLELAND & NAUGHTON, LLP



Daniel A. Geselowitz, Ph.D.

Agent for Applicants

Reg. No. 42,573

Atty. Docket No. 910094RI
1725 K Street, N.W., Suite 1000
Washington, DC 20006
Tel: (202) 659-2930
Fax: (202) 887-0357
DAG/plb

Enclosures: PTO-1449 and 2 references (1 with a translation)